Navigating French Healthcare Systems Successfully 

French Healthcare System for Molecular Oncology Diagnostics

France operates a highly centralised healthcare system with universal coverage provided through the Statutory Health Insurance (SHI) framework. National institutions define healthcare policies, reimbursement rules and evaluation processes, while regional authorities coordinate healthcare delivery and implementation.

This report explains how molecular oncology diagnostics move from regulatory approval to clinical adoption and reimbursement within the French healthcare system, analysing the institutional landscape, Health Technology Assessment processes and reimbursement pathways governing innovative diagnostics.

France’s healthcare model combines strong national governance with regional implementation. Manufacturers introducing innovative molecular diagnostics must therefore navigate a structured policy environment involving multiple national agencies, reimbursement catalogues and early-access funding mechanisms.

The report provides a detailed overview of the institutional actors, evaluation frameworks and strategic pathways that determine whether innovative diagnostics reach clinical practice in France.

Key Insights

Why Market Access in France Is Complex

France’s healthcare system combines universal statutory coverage with strong central governance. National authorities define healthcare policy, reimbursement rules and evaluation frameworks, while regional authorities coordinate healthcare delivery.

The Ministry of Health (Ministère de la Santé) sets national healthcare priorities and allocates funding to Regional Health Agencies (ARS), which implement health policy and oversee care delivery.

Health Technology Assessment plays a critical role in determining whether new diagnostic technologies are reimbursed.

• HAS (Haute Autorité de Santé) evaluates clinical and economic value of new medical technologies.
• CNEDiMTS assesses medical devices and technologies for inclusion in national reimbursement lists.
• CEDiag, created in 2023, evaluates diagnostic tests and IVD technologies.
• CEPS negotiates pricing for reimbursed health technologies.

Understanding how these institutions interact is essential for companies seeking reimbursement for innovative molecular diagnostics.

What This Report Covers

This report provides a comprehensive analysis of the French healthcare system and the pathways governing reimbursement and adoption of molecular oncology diagnostics.

• Healthcare System Structure – Overview of France’s national health insurance framework and institutional governance.
• HTA Evaluation Process – Detailed explanation of the HAS assessment framework and specialised committees.
• Reimbursement Coding Systems – Analysis of national reimbursement catalogues including NABM, CCAM and LPPR.
• Early Access Mechanisms – Explanation of the RIHN 2.0 programme supporting innovative diagnostics.
• Strategic Market Access Insights – Practical guidance for diagnostic manufacturers entering the French market.

Key Stakeholders in the French Healthcare System

The adoption and reimbursement of molecular oncology diagnostics in France involves several national and regional institutions.

• Ministry of Health (Ministère de la Santé) – Defines national health policy and allocates healthcare budgets.
• HAS (Haute Autorité de Santé) – Independent health authority leading Health Technology Assessments.
• UNCAM / CNAM – Public health insurance organisations managing reimbursement systems.
• CEPS – Negotiates pricing for reimbursed technologies.
• Regional Health Agencies (ARS) – Implement national policy and oversee regional healthcare systems.
• INCa – Coordinates national cancer strategies and research initiatives.

Reimbursement Pathways for Diagnostics

France uses several national catalogues to structure reimbursement of medical technologies and diagnostics.

• NABM – Nomenclature for laboratory biological tests such as PCR or NGS.
• CCAM – Coding system for clinical procedures including diagnostic acts.
• LPPR – Reimbursement list for medical devices, reagents and diagnostic kits.

For innovative diagnostics not yet included in standard reimbursement catalogues, the RIHN 2.0 programme provides temporary reimbursement while clinical and economic evidence is generated.

This pathway enables early access to innovative tests while supporting evidence generation required for long-term inclusion in national reimbursement systems.

Who Should Read This Report

• Biotechnology companies developing molecular oncology diagnostics
• Diagnostic manufacturers planning market entry in France
• Market access and reimbursement professionals
• Medical affairs and HEOR teams
• Healthcare strategy and policy analysts
• Investors analysing oncology diagnostic markets

What You Will Gain

This report provides organisations with a structured understanding of how molecular oncology diagnostics are evaluated and reimbursed within the French healthcare system.

• Strategic overview of France’s healthcare governance structure
• Understanding of HTA evaluation processes
• Insights into reimbursement catalogues and coding systems
• Guidance for early access strategies and RWE generation
• Practical perspectives on diagnostic adoption across France

Inside the Report

This report delivers a structured analysis of the French healthcare landscape for molecular oncology diagnostics, combining policy insights, reimbursement pathways and strategic perspectives.

Audio Summary

🎧 Listen: Navigating French Oncology – Access and Reimbursement for Diagnostics

Frequently Asked Questions